Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Current Deferred Revenue (2016 - 2019)

Kiora Pharmaceuticals' Current Deferred Revenue history spans 5 years, with the latest figure at -$2.7 million for Q4 2019.

  • For Q4 2019, Current Deferred Revenue fell 200.0% year-over-year to -$2.7 million; the TTM value through Dec 2019 reached -$2.7 million, down 200.0%, while the annual FY2019 figure was -$2.7 million, 200.0% down from the prior year.
  • Current Deferred Revenue reached -$2.7 million in Q4 2019 per KPRX's latest filing, down from $2.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $12.3 million in Q4 2017 to a low of -$2.7 million in Q4 2019.
  • Average Current Deferred Revenue over 5 years is $4.2 million, with a median of $2.7 million recorded in 2018.
  • Peak YoY movement for Current Deferred Revenue: soared 245.7% in 2017, then plummeted 200.0% in 2019.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.9 million in 2015, then skyrocketed by 121.49% to $4.2 million in 2016, then skyrocketed by 191.45% to $12.3 million in 2017, then crashed by 78.19% to $2.7 million in 2018, then tumbled by 200.0% to -$2.7 million in 2019.
  • Per Business Quant, the three most recent readings for KPRX's Current Deferred Revenue are -$2.7 million (Q4 2019), $2.7 million (Q4 2018), and $2.7 million (Q3 2018).